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SOD 1   copper-zinc superoxide dismutase 
SOD 2   manganese-superoxide dismutase 
SPSS   Statistical Package for Social Sciences 
STZ   streptozotocin 
T cells   transmission cells 
TBARS  thiobarbituric acid reactions 
TBS   tris buffer saline 
TBST   tris buffer saline-tween 20 
TBS/Tx  tris buffer saline-triton X-100 
TCA   trichloroacetic acid 
TEMED  N, N, N’N’-tetramethylenediamine 
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TGF-β   transforming growth factor-β 
TMB   3,3',5,5'-tetramethylbenzidine 
TNF-α   tumour necrosis factor-α 
TrkB   tropomysin-related kinase B 
Tyr   tyrosine kinase 
VEGF   vascular endothelial growth factor 
VmPO   posterior division of the ventromedial nucleus 
VPI   ventroposterior 
VPL   ventroposterolateral 
VPM   ventroposteromedial 
WB   western blot 
WDR   wide-dynamic-range 
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PERUBAHAN EKSPRESI PROTEIN DREAM DAN BDNF, SITOKIN PRO-
KERADANGAN DAN TEKANAN OKSIDATIF DALAM KORDA SPINA 
TIKUS NEUROPATI DIABETES YANG MENYAKITKAN YANG 
DIARUHKAN OLEH STREPTOZOTOCIN DENGAN RAWATAN 
MINOCYCLINE DAN IFENPRODIL 
 
ABSTRAK 
 
Neuropati diabetes (DN) merupakan komplikasi jangka panjang penyakit 
diabetes melitus (DM) yang menyebabkan kesakitan (PDN) atau sebaliknya (non-
PDN). Kajian ini bertujuan untuk meneroka peranan (i) penanda bio protein 
(keseluruhan subunit NR2B (NR2B) dan subunit NR2B yang telah difosforilasi 
(phospho-NR2B) daripada reseptor NMDA, pengaktifan mikroglia, protein BDNF dan 
DREAM), (ii) sitokin pro-keradangan (IL-1β dan TNF-α) dan (iii) status stres oksidatif 
(MDA, SOD dan ‘catalase’) dalam patogenesis DN pada korda spina tikus diabetes 
yang diaruhkan oleh ‘streptozotocin’. Seratus enam puluh lapan ekor tikus jantan 
Sprague-Dawley dibahagikan kepada tujuh kumpulan (n=24), terdiri daripada 
kumpulan bebas diabetes (S+CB), kumpulan kawalan PDN (S+STZ), kumpulan 
kawalan tidak mengalami PDN (non-PDN), kumpulan PDN dirawat dengan 
minocycline (M80 dan M160) atau ifenprodil (I0.5 dan I1.0). DM diaruhkan dengan 
satu suntikan ‘streptozotocin’ (60mg/kg). Ujian tingkah laku kesakitan seperti Von 
Frey, plat-panas dan formalin dilakukan untuk menilai ‘allodynia’ sentuhan, 
hiperalgesia terhadap haba dan bahan kimia. Rawatan ‘saline’, minocycline (80 atau 
160µg sehari) atau ifenprodil (0.5 atau 1.0µg sehari) diberikan secara suntikan 
intratekal selama tujuh hari. Selepas itu, kesakitan keradangan kronik telah diaruhkan 
dengan suntikan formalin dan tikus-tikus tersebut telah dikorbankan tiga hari 
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kemudian. Bahagian pembesaran lumbar pada korda spina tikus dibedah keluar untuk 
tujuan penganalisaan. Keputusan kajian menunjukkan tikus PDN mengalami 
‘allodynia’ sentuhan dan hiperalgesia terhadap bahan kimia tetapi tidak terhadap haba, 
yang mana simptom tersebut telah direncat oleh minocycline dan ifenprodil. 
Sementara itu, tikus non-PDN tidak mengalami ‘allodynia’ sentuhan dan hiperalgesia 
terhadap haba mahupun bahan kimia. Ekspresi protein NR2B, phospho-NR2B, 
pengaktifan mikroglia, BDNF dan DREAM menunjukkan peningkatan drastik pada 
bahagian ipsilateral dan kontralateral korda spina dalam kumpulan (S+STZ) dan 
keputusan ini bertentangan dengan keputusan daripada kumpulan non-PDN. 
Minocycline dan ifenprodil berjaya mengurangkan ekspresi NR2B, phospho-NR2B, 
BDNF, DREAM dan pengaktifan mikroglia pada bahagian ipsilateral dan kontralateral 
korda spina tikus PDN bergantung pada dos yang diberikan. Tambahan pula, 
kumpulan-kumpulan (S+STZ) dan non-PDN menunjukkan peningkatan yang 
signifikan terhadap kadar TNF-α namun menunjukkan tiada perubahan pada kadar IL-
1β. Minocycline telah berjaya merencatkan peningkatan rembesan kedua-dua sitokin 
tersebut manakala ifenprodil telah merencatkan peningkatan kadar TNF-α namun 
meningkatkan pula kadar IL-1β. Selain itu, kadar MDA meningkat secara signifikan 
dalam kumpulan-kumpulan (S+STZ) dan non-PDN. Pengurangan aktiviti enzim 
‘catalase’ dengan tiada perubahan pada aktiviti enzim SOD dikesan dalam kumpulan 
(S+STZ) manakala peningkatan aktiviti enzim ‘catalase’ dengan pengurangan aktiviti 
enzim SOD dilihat dalam kumpulan non-PDN. Minocycline dan ifenprodil 
mengurangkan kadar MDA dan meningkatkan aktiviti enzim-enzim ‘catalase’ dan 
SOD pada korda spina. Secara tuntasnya, minocycline dan ifenprodil berkesan 
merawat PDN melalui aktiviti-aktiviti anti-kesakitan, anti-oksida dan anti-keradangan 
yang telah ditunjukkan dalam penyelidikan ini. 
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CHANGES OF DREAM AND BDNF PROTEINS EXPRESSIONS, PRO-
INFLAMMATORY AND OXIDATIVE STRESS LEVELS IN SPINAL CORD 
OF STREPTOZOTOCIN-INDUCED PAINFUL DIABETIC NEUROPATHY 
RATS UPON MINOCYCLINE AND IFENPRODIL TREATMENTS 
 
ABSTRACT 
 
Diabetic neuropathy (DN) is a long-term complication of diabetes mellitus 
(DM) which could be painful (PDN) or non-painful (non-PDN). This study aimed to 
explore the effect of minocycline and ifenprodil on the (i) proteins expressions of 
NR2B subunit (NR2B) and phosphorylated NR2B subunit (phospho-NR2B) of N-
methyl-D-aspartate (NMDA) receptors, microglial activation, brain-derived 
neurotrophin factor (BDNF) and Downstream Regulatory Element Antagonist 
Modulator (DREAM) proteins), (ii) pro-inflammatory cytokines (interleukin-1β (IL-
1β) and tumour necrosis factor-α (TNF-α) and (iii) oxidative stress markers 
(malondialdehyde (MDA), superoxide dismutase (SOD) and catalase) in the 
pathogenesis of DN in the spinal cord of streptozotocin-induced diabetic rats. One 
hundred and sixty-eight Sprague-Dawley male rats were assigned into seven groups 
(n=24) consisting of non-diabetic control (S+CB), diabetic PDN control (S+STZ), 
diabetic non-PDN control (non-PDN), minocycline-treated PDN groups (M 80 and M 
160) and ifenprodil-treated PDN groups (I 0.5 and I 1.0). DM was induced with a 
single streptozotocin injection at 60 mg/kg. Nociceptive behavioural tests such as Von 
Frey, hot-plate and formalin tests were conducted to assess tactile allodynia, thermal 
hyperalgesia and chemical hyperalgesia respectively. Treatment of either saline, 
minocycline (80 µg/day or 160 µg/day) or ifenprodil (0.5 µg/day or 1.0 µg/day) was 
administered intrathecally for seven days. Chronic inflammatory pain was induced 
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with formalin injection before being sacrificed three days later. The spinal cord lumbar 
enlargement region was collected for immunohistochemistry, Western Blot (WB) and 
enzyme-linked immunoabsorbent assay (ELISA) analyses. The results showed that 
PDN rats developed tactile allodynia and chemical hyperalgesia but not thermal 
hyperalgesia, in which were prevented by minocycline and ifenprodil at both lower 
and higher doses used. Meanwhile, non-PDN group showed lower tactile allodynia, 
thermal and chemical hyperalgesia. There was significant higher NR2B, activated 
microglia, BDNF and DREAM proteins ipsilaterally and contralaterally by 
immunohistochemistry and WB analyses in (S+STZ) group, in which the results were 
reduced in non-PDN group. Minocycline and ifenprodil at both lower and higher doses 
significantly attenuated the expressions and mean relative NR2B, phospho-NR2B, 
BDNF, DREAM proteins levels and activated microglial positive neurons in a dose-
dependent manner. Furthermore, (S+STZ) and non-PDN groups showed a significant 
higher TNF-α level. Minocycline inhibited both cytokines. Moreover, MDA level was 
significantly higher in (S+STZ) and non-PDN groups. Significant lower catalase 
enzyme activity with insignificant SOD enzyme activity was detected in (S+STZ) 
group whilst marked higher catalase activity with lower SOD enzyme activity were 
detected in non-PDN group. Minocycline and ifenprodil attenuated MDA level and 
lead to higher catalase and SOD activities in the spinal cord. In conclusion, 
minocycline and ifenprodil is effective to combat PDN through their strong anti-
nociceptive, anti-oxidant and anti-inflammatory activities as has been shown in this 
study.
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CHAPTER ONE 
INTRODUCTION 
 
 
1.1 Diabetic neuropathy 
Neuropathic pain is one of the critical problems in clinical medicine as it is not 
easy to cure. It is pathological and defined as a chronic pain state resulting from injury 
or disease of neurons in peripheral or central nervous system (CNS). Neuropathic pain 
may result either from acute events (e.g amputation and spinal cord injury) or systemic 
disease (e.g diabetes, viral infection and cancer) (Zhuo et al., 2011, Ji et al., 2017). 
Patients with neuropathic pain experience devastated suffering as this pathological 
pain is hugely resistant to currently available analgesics. Neuropathic pain is 
characterized by unusual response to somatic sensory stimulation. The patients 
experiencing peripheral neuropathies may feel pain from stimuli which are non-
noxious in normal condition such as a soft touch on the skin or by changes in 
temperature. They also suffer from enhanced responses to pain stimuli. In fact, 
neuropathic pain treatment costs billions dolars annually and most drugs focus on 
reducing the neuronal hyperexcitability either peripherally or centrally. However, 
currently-used medication such as tricyclic antidepressants and the “gold standard” 
gabapentin that are the mainstay of neuropathic pain treatment, has been shown to be 
limited in efficacy and produces several side-effects in a number of patients (Childers 
and Baudy, 2007; Kukkar et al., 2013).  
One of the devastating diseases classified under neuropathic pain is diabetic 
peripheral neuropathy (DPN). Diabetic neuropathy is a late complication of diabetes 
mellitus (DM) of either Type I or II.  A study from the Mayo Clinic revealed that 
diabetic neuropathies are common in diabetic patients affecting approximately 66% 
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with insulin-dependent DM (Type I DM) and 59% in patients with non-insulin-
dependent DM (Type II DM) (Sadosky et al., 2008). Moreover, PDN is reported to 
affect approximately 18% of adult diabetic patients compared with a minimum of 30% 
of patients with overall diabetic peripheral neuropathy (Spallone and Greco, 2013). In 
fact, numerous types of diabetic neuropathy have been reported including cranial, 
truncal, focal limb and amyotrophic neuropathy (Jensen et al., 2006). However, in 
specific, the sensory neuropathy, which is also referred to as distal symmetric sensory 
polyneuropathies, may be further classified as being acute or chronic. But, chronic 
form is actually the most common occurrence of diabetic neuropathy including painful 
diabetic neuropathy (PDN), which occupies most of the available epidemiologic data 
(Sadosky et al., 2008).  
Neuropathic pain has raised the question of whether a completely different 
strategy is needed and could offer an alternative approach to obtain a better treatment 
outcome. Pain expert panel has identified a number of deficiencies in the available 
clinical data that need serious attention, including the lack of understanding of the 
underlying mechanisms of PDN and the need for studies to investigate the treatment 
effects on different symptoms of PDN such as allodynia, hyperalgesia and spontaneous 
pain (Jensen et al., 2006). Thus, it is crucial to deeply explore and understand the 
pathogenesis underlying PDN together with the discovery of new molecular targets 
that potentially give some hope to the patients and also strengthen the demand for 
alternative way for curing neuropathic pain. 
In year 1991, the glial cell has become the centre of researchers’ attention since 
an animal model of neuropathic pain was reported to stimulate spinal astrocytes 
activation (Garrison et al., 1991). During that period, the drugs experimented also 
demonstrated attenuation towards numbers of astrocytic activation in the rat model of 
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sciatic nerve constriction injury (Garrison et al., 1994). Beginning from that, glial cell 
activation was believed to be strongly connected with the development of neuropathic 
pain. To be specific, microglial activation in neuropathic pain has been widely 
investigated and research discovered evidence that glial cell are the key players in the 
creation and maintenance of several types of neurodegenerative diseases. The 
discovery of spinal cord glial cells which strongly implicates pain processing enhances 
the understanding of pain, including understanding the glia-neuron interactions. In 
fact, as microglia could possibly modulate pain, it is vital to understand the 
mechanisms of microglial activation on the pathogenesis of neuropathic pain, 
especially on PDN. Inhibiting the microglial activation could potentially one of the 
possible ways to combat the development of PDN. Therefore, understanding this 
mechanism leading to the pathogenesis of PDN should be well-studied. 
Apart from that, N-methyl-D-aspartate (NMDA) receptors activation has been 
implicated in the initiation and maintenance of central sensitization during the pain 
states. Understanding the molecular and cellular mechanisms of NMDA receptors may 
give some hope to the pain analgesic development targeting these receptors to combat 
PDN. In brief, NMDA receptors are composed of three subunits: NR1, NR2 (A, B, C 
and D) and NR3 (A and B) subunits which play different roles whether in pain 
transmission or in learning and memory. NR2B subunit of NMDA receptor is reported 
to be abundantly expressed in the spinal dorsal horn and have more implications for 
neuropathic pain (Ma and Hangreaves, 2000). Since NR2B subunit receptor are 
located at the extra synaptic sites, it is possible that its effect differs from the other 
types of NMDA receptor subunits (Parsons and Raymond, 2014). The development of 
drugs specifically targeting this site may aid in alleviating pain in patients with PDN. 
Last but not least, the previous studies on the mechanisms of neuropathic pain revealed 
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the involvement of signalling neuromodulators such as brain-derived neurotrophic 
factor (BDNF) and downstream regulatory element antagonist modulator (DREAM) 
in the neuron-glia crosstalk (Zhang et al., 2007, Ren and Dubner, 2008, Tsuda, 2016). 
It is possible that the pathogenesis of PDN is also similar to the other models of 
neuropathic pain in which the signalling neuromodulators may play the similar roles 
for the neuron-glia interactions. If so, inhibiting these signalling molecules leading to 
the activation of NR2B subunit of NMDA receptor as well as microglia may perhaps 
bring some hope to combat the development of PDN. 
  
1.2 Problem statements 
It is already known worldwide that neuropathic pain, specifically PDN, is not 
easy to be treated. The mechanisms underlying PDN are still unclear. However, the 
previous studies of neuropathic pain revealed strong neuronal and non-neuronal 
interactions leading to the development and maintenance of neuropathic pain (Hossain 
et al., 2017, Ji et al., 2017). The neuronal mechanisms involving the spinal NMDA 
receptor activation especially NR2B subunit activation has been revealed to play a 
vital role in initiating and maintaining the neuropathic pain (Qu et al., 2009) as the 
persistent NR2B subunit of NMDA receptor activation causes the stimulation of non-
neuronal cells (i.e microglial activation) through the cascades of immune system 
activation (Hossain et al., 2017, Ji et al., 2017). These interactions are also succeeded 
by the aid of signalling neuromodulators such as BDNF and DREAM proteins, free 
radicals and pro-inflammatory cytokines released by these neuronal and non-neuronal 
cells to interact with each other in the pathogenesis of neuropathic pain (Geng et al., 
2010, Old and Malcangio, 2012). 
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By targeting neuronal and non-neuronal interactions, it is believed that the 
pathogenesis of PDN can be combated. Therefore, the drugs targeting these neuronal 
and non-neuronal pathways is needed to inhibit the development of painful diabetic 
neuropathy. Ifenprodil has been demonstrated in the previous study of neuropathic 
pain model to possess a greater selectivity for NR2B subunit of NMDA receptor 
activation compared to other similar antagonists (Boyce et al., 1999) to non-
competitively inhibit this NMDA receptor activation. Meanwhile, minocycline has 
been shown to strongly inhibit the microglial activation in the animal models of 
neuropathic pain (Pabreja et al., 2011, Taves and Ji, 2016). However, the effects of 
these drugs in inhibiting the development of PDN is not clear. It is also unknown 
whether these drugs may have some effect on the signalling neuromodulators such as 
DREAM and BDNF proteins expressions, pro-inflammatory cytokines and oxidative 
stress markers to interrupt the interactions between neuronal and non-neuronal 
mechanisms, therefore, may possibly combat the development of PDN. 
 
1.3 Objectives of the study 
1.3.1 Main objective 
Thus, the main objective of this study was to explore the roles of protein 
biomarkers (NR2B subunit of NMDA receptor phosphorylation and activation, 
microglial activation, BDNF and DREAM proteins), oxidative stress 
(malondialdehyde, superoxide dismutase and catalase enzymes activities) and pro-
inflammatory markers (interleukin-1β and tumour necrosis factor- α). This study also 
aimed to explore the anti-nociceptive, anti-inflammatory and anti-oxidant effects of 
ifenprodil and minocycline and to determine whether the signalling pathways of 
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BDNF and DREAM protein expressions, pro-inflammatory cytokines and oxidative 
stress were involved in the spinal cord of STZ-induced PDN rat.  
 
1.3.2 Specific objectives 
1. To compare the effects of ifenprodil and minocycline administered 
intrathecally on tactile allodynia, thermal hyperalgesia and formalin-induced 
inflammatory nociceptive behaviour in the STZ-induced PDN rats. 
2. To compare the effects of ifenprodil and minocycline administered 
intrathecally on the microglial cell marker expression (OX-42), total 
expression of NR2B subunit of NMDA receptors, phosphorylation of NR2B 
subunit of NMDA receptors, BDNF and DREAM proteins expression by 
immunohistochemistry and western blot analyses in the spinal cord of STZ-
induced PDN rat. 
3. To compare the effects of ifenprodil and minocycline administered 
intrathecally on the pro-inflammatory markers level of interleukin-1β (IL-1β) 
and tumour necrosis factor-α (TNF-α), oxidative stress markers 
(malondialdehyde (MDA) level and catalase and superoxide dismutase (SOD) 
enzymes activities). 
4. To correlate the microglial cell marker (OX-42), total NR2B subunit of NMDA 
receptors, phosphorylation of NR2B subunit of NMDA receptors, BDNF and 
DREAM proteins expression, IL-1β and TNF-α levels, MDA level, catalase 
and SOD enzymes activities in the spinal cord with tactile allodynia, thermal 
hyperalgesia and formalin-induced inflammatory nociceptive behaviour in the 
STZ-induced PDN rat. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Pain 
Pain, whether originates physiologically or pathologically is an unpleasant 
sensory experience stimulated with the presence of noxious stimuli. The increasing 
prevalence of pain, particularly chronic pain, is seriously alarming and appears to 
increase with age in both men and women (Schim and Stang, 2004). It could be the 
most probable reason of why patients seek medical consultation. According to the 
International Association for the Study of Pain (IASP), pain is defined as ‘an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage’ (Williams and Craig, 2016). 
 
2.1.1 Pain pathways 
In general, pain pathways consist of pain signal transduction at the peripheral 
receptor site, pain signal conduction along the peripheral nerve, pain modulation at 
spinal cord level, pain perception at the supraspinal site and lastly, the related 
emotional feelings, sensation and affective state (Kitahata, 1993).  
 
2.1.1(a) Pain signal transduction at the peripheral receptor site 
 The propagation of pain is actually elicited with the activation of nociceptors 
found abundantly in the skin (epidermis, dermis), dental pulp, mucosal membranes of 
the oral and nasal cavities of the respiratory, gastrointestinal, and urinary tracts, 
muscles, tendons, ligaments, joint capsules and bones. These nociceptors are naked 
and free nerve endings and respond only when a stimulus is sufficiently strong to cause 
injury. Three main categories of primary afferent fibres are Aβ-fibre, Aδ-fibre and C-
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fibre. These fibres which are also the first-order neurons are classified depending on 
the diameter, structure and conductivity speed.  
Myelinated Aβ-fibres are the greatest fibre diameter and the highest speed of 
conductivity compared to the other types of primary afferent fibres. The Aβ-fibres are 
responsible for the touch sensation. Meanwhile, myelinated Aδ-fibres carry 
mechanical and thermal stimuli (pain) from the peripheral nerve. This type of fibres 
promotes an immediate sensation of the first phase or acute pain and initiate 
withdrawal actions. Two distinctive types of Aδ fibres were discovered; Type I of Aδ 
fibres respond to fibres with high-threshold mechanoreceptors that mainly respond to 
the mechanical input of high intensity and weakly respond to thermal or chemical 
inputs. Meanwhile, another type of Aδ fibres, Type II is the fibres with 
mechanothermal receptors for strong heat (45-53 ⁰C) and some receptors for the 
extreme cold (-15 ⁰C) and sensitized to vigorous mechanical stimuli at non-noxious 
thresholds (Millan, 1999). Aδ fibres propagate the ‘fast pain’ in which they transmit 
the pain inputs fairly quickly. Meanwhile, C-fibres possesses several distinctive 
characteristics and response to thermal and mechanical stimuli. Majority of C-fibres 
with high-threshold receptors respond equivalently to thermal and mechanical stimuli 
or are sensitive to mechanical, thermal and chemical inputs (polymodal C-fibres). 
There is also another special type of polymodal C-fibres that react to high-intensity 
thermal stimuli and seems accountable for sudden brief burst of response after the 
tissue injury. Apart from that, there is also another type of C-fibres that are slowly 
conducted, insensitive to mechanical stimuli, mediated by histamine and possibly 
involved in the burning sensation. Last but not least is another type of C-fibres which 
do not respond to noxious input in general, but become merely activated in the 
presence of inflammation (silent C-fibres) (Willis and Westlund, 1997, Almeida et al., 
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2004, Millan, 1999). The unmyelinated C-fibres mediate nociceptive inputs in a slower 
manner or ‘slow pain’, at times secondary to the action of Aδ fibres (Almeida et al., 
2004).   
 
2.1.1(b) Signal conduction of pain 
In brief, the sensory pathway as shown in Figure 2.1 is classified into three sections 
which are: 
1) First-order neurons that carry sensory inputs from the nociceptive receptor to 
the CNS. 
2) Second-order neurons which transmit the nociceptive signal from CNS to the 
thalamus. 
3) Third-order neurons that propagate the nociceptive input from the thalamus to 
the cerebral cortex. 
First-order neurons propagate the nociceptive inputs from the peripheral nerve to the 
spinal cord and the brainstem via the cranial nerve pairs V, VII, IX and X. The first-
order neurons will detach from the thicker fibres, organizing themselves in the 
ventrolateral bundle of roots and then form synapses with second-order neurons 
distributed along the dorsal horn of the spinal cord (Merskey, 1986). 
 The axons of second-order neurons form afferent bundles with anterolateral or 
posterior fascicle that project the pain impulse to brainstem and diencephalon 
structures including thalamus, periaqueductal substance, parabrachial region, reticular 
formation of the medulla, amygdaloid complex, septal nucleus and hypothalamus. The 
previous findings indicated that the axons of second-order neurons project either in the 
direct (spinothalamic) or indirect (spinoreticular) pathway of the anterolateral system, 
or as three sets of fibres which are the spinomesenphalicspinotectal or spinohypothala- 
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Figure 2.1 First-, second- and third-order neurons in pain pathways. First-order 
neurons carry the sensory inputs from nociceptor to the CNS whilst 
second-order neurons transmit the nociceptive inputs from the CNS to 
thalamus. Meanwhile, third-order neurons propagate the nociceptive 
signals from the thalamus to cerebral cortex. Adapted from Chan 
(2010). 
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mic fibres (the remaining components of the anterolateral system). These tracts are 
believed to propagate noxious, thermal and crude tactile signals to the higher brain 
centres. Almost 15% of the afferent fibres propagate directly to the thalamus whilst 
85% of the afferent fibres project to the thalamus through a relay in the reticular 
formation (Millan, 1999).   
 
Direct pathway of the anterolateral system 
 Aδ-fibres of the first-order neurons synapse mainly with second-order neurons 
in lamina I (posteromarginal nucleus) and lamina V (reticular nucleus) of the spinal 
cord. But most of these first-order neurons synapse with the spinal cord interneurons 
that are related to a reflex motor activity. The axons of the second-order neurons are 
then projected across the midline to the contralateral side of the spinal cord in the 
anterior white commissure to form the spinothalamic tract. 
In brief, spinothalamic tract (neospinothalamic pathway) is comprised of the 
lateral spinothalamic tract (found in the lateral funiculus) and anterior spinothalamic 
tract (found in the anterior funiculus). This tract disseminates noxious, thermal and 
crude touch signals to the contralateral ventral posterior lateral nucleus of the 
thalamus. Apart from that, spinothalamic tract also transmits the information to the 
ventral posterior inferior and the intralaminar nuclei of the thalamus. Although the 
spinothalamic tract terminates in the thalamus, this tract also transmits collaterals to 
the reticular formation as if ascends via brainstem (Tortora and Derrickson, 2008).  
 
Indirect pathway of the anterolateral system 
Unmyelinated C-fibres of the first-order neurons end on the interneurons in 
lamina I (substantia gelatinosa) and lamina II of the dorsal horn. The axons of these 
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interneurons then synapse with second-order neurons in laminae V-VIII. Most of these 
axons ascend ipsilaterally but some project to the contralateral side of the spinal cord 
in the anterior white commissure. These axons form the more pronounced ipsilateral 
and smaller contralateral spinoreticular tracts (paleospinothalamic pathway). The 
spinoreticular tract propagates the noxious, thermal and crude touch inputs from the 
spinal cord to the thalamus in an indirect pathway by forming abundant synapses in 
the reticular formation before projecting to the thalamus (Abbracchio and Reggiani, 
2013). 
 Third-order neurones are situated in the ventral posterior lateral nucleus of the 
thalamus and ascend in the posterior limb of the internal capsule and corona radiata to 
end in the primary somatosensory cortex of postcentral gyrus (SI). The primary 
somatosensory cortex is then projected to the secondary somatosensory cortex (SII) 
situated on the superior border of the lateral fissure. Some of the third-order neuron 
fibres from the thalamus may also directly terminate in the SII (Almeida et al., 2004, 
Perl, 2011).  
 
2.1.1(c) Modulation at the spinal cord level 
It is believed that the dorsal horn of the spinal cord is the first site of modulation 
for the pain signal arriving from the periphery to CNS (Kitahata, 1993). To understand 
the process of pain modulation in the spinal cord, Melzack and Wall (1967) have 
proposed the ‘gate control theory’ to understand the pain modulation process in a better 
way (Figure 2.2). 
The pain impulse reaching the spinal cord is transmitted to three dominant 
spinal cord systems which are: 
1) cells of the substantia gelatinosa (SG) in the dorsal horn 
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Figure 2.2 Schematic diagram of the gate control theory of pain mechanisms. L = 
large diameter Aβ-fibres, S = small diameter Aδ- and C-fibres, T = 
transmission cells, SG = cells of substantia gelatinosa, (+) = excitation 
and (—) = inhibition. The inhibitory effect employed by SG cells on 
the afferent fibre terminals is elevated by the activity in ‘L’ fibres and 
reduced by the activity in ‘S’ fibres. The line running from the large 
fibre system to the central control mechanisms represents ‘central 
control’, and these mechanisms in turn, propagate back to the gate 
control system. T cells propagate to the entry cells of the action system. 
Adapted from Melzack and Wall (1967). 
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2) dorsal-column fibres that project toward the brain (central control) 
3) first central transmission (T) cells in the dorsal horn 
It is proposed that SG acts as a gate control system that modulates the afferent patterns 
before they affect the T cells. Meanwhile, the afferent patterns in the dorsal column 
system functions as a central control trigger that may stimulate selective brain 
processes that affect the modulation properties of the gate control system. 
Furthermore, T cells may stimulate neural pathways which consist of the action system 
accountable for response and perceptions. 
 In gate control theory, the afferent fibres (Aβ-, Aδ- and C-fibres) that carry 
noxious signals project to SG and T cells. T cells propagate the noxious signals up to 
the brain whilst SG cells (inhibitory interneurons) prevent the pain signal transmission. 
Activities in C, Aδ- and Aβ-fibres influence activities in the T cells in which thin 
diameter Aδ- and C-fibres excite the SG cells (tend to allow T cells to fire) while large-
diameter myelinated Aβ-fibres excite the inhibitory SG cells (tend to attenuate T cells 
activity). Briefly, the activation of non-noxious large diameter Aβ-fibres may disturb 
the signals from pain fibres (Aδ- and C-fibres), therefore inhibiting pain. 
 The laminae of the spinal cord which are involved in receiving pain inputs from 
Aδ- and C-fibres, also receive the signals from Aβ-fibres. Aβ-fibres indirectly 
attenuate the effects of Aδ- and C-fibres, ‘closing a gate’ to the propagation of their 
pain inputs. In addition, in other parts of the laminae, the Aδ- and C-fibres also 
suppress the effects of Aβ-fibres, thus ‘opening the gate’. This happens when the 
output of the T cells exceeds a critical level thus allowing the pain transmission to the 
brain. 
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2.1.1(d) Descending pain inhibition 
Research has established that the stimulation of midbrain and medullary sites 
exerts dual control over nociception. Descending pain pathways (as indicated by red- 
and green-coloured pathway in Figure 2.3) communicate from the brain to the body 
which attenuates pain. There are a minimum of two major pathways that descend to 
the spinal cord to suppress the projection of pain. The most significant descending 
pathway starts in the periaqueductal gray (PAG). The neurons beginning in the PAG 
terminate on cells in the medulla including the serotonergic cell bodies of the raphe 
nuclei (Figure 2.3). The serotonergic neurons then descend the spinal cord to attenuate 
cell firing. Other cells in the PAG end next to the locus coeruleus in the brainstem. 
PAG functions to receive inputs from higher brain centres and is able to activate a 
strong analgesic effect without affecting the body’s ability to detect temperature, 
pressure or touch (Zhuo, 2008, Ossipov et al., 2014). This is proven by early research 
that microinjection of opioids into PAG attenuates the neuropathic pain perceived by 
rats (Yaksh et al., 1976, Lewis and Gebhart, 1977). The microinjection of morphine 
into PAG after the application of peripheral pain stimuli also demonstrated a marked 
attenuation of dorsal horn second-order neurons activity (Bennett and Mayer, 1979).  
Other than that, rostro ventromedial medulla (RVM) comprises the 
serotonergic nucleus raphe magnus (NRM), nucleus reticularis gigantocellularis-pars 
alpha and nucleus paragiganto-cellularis lateralis (Vanegas and Schaible, 2004). RVM 
is capable of either facilitating or attenuating the pain signals and functions as a final 
relay in the control of descending pain facilitation (Ossipov et al., 2014).  
 
 
 
16 
 
 
 
 
Figure 2.3 Descending pain pathway. Descending pain pathways (as indicated by 
red- and green-coloured pathway) communicate from the brain to the 
body which attenuates pain. There are at minimum of two major 
pathways that descend to the spinal cord to suppress the projection of 
pain. The most significant descending pathway starts in periaqueductal 
gray (PAG). The activation of PAG has been shown to result in 
analgesia, but exhibit no change in the ability to detect temperature, 
pressure or touch. The neurons begin in the PAG terminate on cells in 
the medulla including the serotonergic cell bodies of the raphe nuclei. 
The serotonergic neurons then descend into spinal cord to attenuate cell 
firing. Other cells in the PAG end next to the locus coeroleus in the 
brainstem. Adapted from Zhuo (2008). 
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In a neuropathic pain model of spinal nerve ligation, tactile allodynia that is 
developed after unilateral ligation of L5 and L6 spinal nerves was found to be attenuated 
by inactivation of the RVM by lidocaine injection (Pertovaara, 1998). PAG may affect 
the descending pain modulation mainly via its mutual connection with RVM. The 
trigger of PAG neurons may also trigger the activity of RVM neurons and is related to 
the attenuation of nocifensive reflexes in rats (Behbehani and Fields, 1979). Jensen 
and Yaksh (1986) through their research, demonstrated that morphine blocked the 
nocifensive input to thermal noxious stimuli when it is microinjected into RVM of the 
rat since RVM has neuronal communication with the PAG. Furthermore, similar to the 
‘gate control theory’ proposed by Melzack and Wall (1967), the modulation of 
nociceptive responses by RVM is assisted by two distinguished populations of 
neurons: ON and OFF cells. ON cells are accountable for the facilitatory effect on the 
nociceptive processing via descending systems projecting to the spinal cord (Ossipov 
et al., 2000, Ossipov et al., 2014). Meanwhile, OFF cells are assumed to comprise a 
descending inhibitory system that block nociceptive input directly at the level of the 
spinal cord (Fields et al., 1991, Ossipov et al., 2000), for example, OFF cells attenuate 
firing immediately prior to the tail-flick in rats (Ossipov et al., 2014). 
Although the descending pain facilitatory and inhibitory systems maintain a 
homeostatic state, the occurrence of illness, injury or inflammation can disturb this 
balance. Studies have revealed that persistent pain after tissue or nerve damage is 
related to the amplified activation of descending modulatory circuits (Vanegas and 
Schaible, 2004, Guo et al., 2006). Injury or inflammation may enhance RVM ON-cell 
activity. Moreover, the pharmacological, neurochemical and physical disturbance of 
descending facilitation from RVM diminishes the enhanced behavioural responses to 
the evoked stimuli without inhibiting the acute, protective nociceptive reflex (Ossipov 
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et al., 2014). This increased nett descending facilitatory drive contributes to the 
augmentation and spread of pain (Vanegas and Schaible, 2004, Guo et al., 2006).  
Descending noradrenergic projections to the spinal dorsal horns communicate 
with RVM and PAG. Recent findings suggest that during the nerve injury, the activity 
of descending noradrenergic system is enhanced in an effort to compensate for the 
enhanced nociceptive signals. The injury causes the increased synthesis and 
production of noradrenaline along with an increased efficacy of spinal α2-adrenergic 
receptors (Muto et al., 2012). 
 
2.1.1(e) Perception at the supraspinal sites 
Previous studies indicate that supraspinal structure involved in pain comprises 
the midbrain, brainstem, thalamus, hypothalamus, lentiform nucleus, somatosensory 
cortex, insular cortex and pre-frontal, anterior and parietal cingulate cortex (Almeida 
et al., 2004, Zhuo et al., 2011).  
Thalamus is believed to be the primary relay structure for sensory inputs 
transmitted to the cortex and involved in the reception, integration and the transfer of 
nociceptive potential. The lateral nuclear complex of the thalamus is comprised of 
three types of nuclei; ventroposterolateral (VPL), ventroposteromedial (VPM) and 
ventroposterior (VPI) nuclei. These nuclei respond to thermal and mechanical stimuli 
and some also respond to freezing (Almeida et al., 2004). It is well-known that VPL 
and VPM are involved in the inhibitory interactions which form a modulatory system 
in the propagation of pain to superior centres, similar to the proposed ‘gate control 
theory’. The afferent fibres from the spinocervical tract, spinoparabrachial tract and 
spinoreticular tract are also projected to the lateral complex of the thalamus (Almeida 
et al., 2004). 
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Meanwhile, the posterior complex of the thalamus is comprised of the pulvinar 
oralis nucleus, posterior nucleus (PO) and the posterior division of the ventromedial 
nucleus (VmPO). PO and VmPO nuclei establish connections with the insular and 
cingulate cortex and contribute to affective cognitive aspects of pain (Treede et al., 
1999, Almeida et al., 2004). In addition, these nuclei are believed to become the 
centres of integration for painful and thermal noxious inputs. The posterior complex 
of the thalamus receives the noxious signals from afferent fibres derived from the 
spinothalamic tract, spinohypothalamic tract, spinoparabarachial tract and 
postsynaptic pathway from the dorsal column (Almeida et al., 2004).  
Furthermore, the medial complex of the thalamus is comprised of the ventral 
region of the dorsal medial nucleus (MDvc), lateral central nucleus (LC) and the 
centromedial nucleus (CM). These nuclei are projecting to the cingular cortex and it is 
proposed that they are involved in the motivational-affective aspects of pain. The 
nuclei of the medial complex of thalamus receive afferent fibres from laminae I and V 
of the spinothalamic tract and interconnect with striatum and cerebellum, possibly 
involved in the escape behaviour in the presence of a dangerous input (Millan, 1999). 
Pain signals mediated by the lateral, posterior and medial systems are then 
projected to three important cortical regions which are SI, SII and anterior cingulate 
cortex (Millan, 1999, Almeida et al., 2004). The lateral system is involved directly in 
the sensory-discriminative attribution of pain and involves specific thalamic nuclei 
which propagate to spinal nerves and wide-dynamic-range neurons (WDR) of the SI 
and SII cortices. The SI and SII cortices are interconnected with the posteroparietal 
area and with the insula via a cortico-limbic somatosensory pathway which is related 
to learning and memory. On the other hand, the medial system has less defined 
projections from the medial complex of the thalamus to SI and SII, including the limbic 
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structures (e.g insula and anterior cingulate cortex). Thus, it is the reason why the 
medial region of thalamus contributes to the motivational-affective component of 
nociception although it may also take part in the sensory-discriminative circuitry 
(Treede et al., 1999). 
The insula functions in receiving the nociceptive inputs from the lateral system 
and propagates to the limbic system, mainly amygdala and some regions of prefrontal 
cortex. These regions are responsible for the emotional and affective component and 
memory associated with the painful experience (Price, 2000). Meanwhile, the anterior 
cingulate cortex functions in bringing the attentional and emotional mechanisms to 
pain experience (Treede et al., 1999). 
  
2.1.2 Types of pain 
 Pain experience according to Kitahata (1993) could be categorized into four 
distinguished types and stages which are: 
1) Processing of acute pain signals (acute physiological nociceptive pain) 
2) Sympathetically maintained pain (pathophysiological nociceptive pain) 
3) Persistent pain stimulation secondary to peripheral tissue damage (chronic 
pain) 
4) Neuropathic pain 
Acute physiological nociceptive pain results from the brief or acute noxious 
mechanical, chemical and/or thermal elicitation of the peripheral receptors. This type 
of pain defends the tissue from further damage as the withdrawal reflexes are 
stimulated (Schaible and Richter, 2004). Furthermore, pathophysiological 
nociceptive pain results as the tissue is inflamed or damaged. The spontaneous pain 
(pain in the absence of any stimulation) and/or hyperalgesia and/or allodynia may 
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appear. Chronic pain may be followed by neuroendocrine dysregulation, fatigue, 
dysphoria and diminished physical and mental performance (Chapman and Gavrin, 
1999). Chronic pain may also result from chronic diseases and possibly result from 
persistent pain processes. Last but not least, neuropathic pain is caused by the 
neuronal injury or disease in the peripheral or central nervous system. Neuropathic 
pain usually transmits abnormal signals felt as burning sensation which tends to be 
acute or prolonged. It may also be combined with allodynia and hyperalgesia. Several 
pathological processes may lead to neuropathic pain namely axotomy or nerve damage 
(e.g spinal cord injury, post-mastectomy pain, post-operative hernia repair pain and 
other types of post-surgical pain),  carpal tunnel syndrome, central pain syndrome (e.g 
stroke and multiple sclerosis), degenerative disc disease (e.g. arthritis), diabetic 
neuropathy, phantom limb pain, postherpetic neuralgia (shingles), pudendal neuralgia, 
sciatica, trigeminal neuralgia, Guillain-Barre syndrome, cancer, kidney disorders, 
alcohol and human-immunodeficiency virus (HIV) (Jacques, 2017). Thus, in the 
present study, we focus in detail on neuropathic pain as the major pathological process 
resulting from DM. 
 
2.2 Neuropathic pain 
Neuropathic pain, according to Merskey (1986), is defined as ‘pain initiated or 
caused by a primary lesion or dysfunction in the nervous system’. The pain is produced 
without any stimulation to the nociceptors or inappropriate response to the stimulation 
of nociceptors (Brannagan III, 2013). The person experiencing neuropathic pain would 
complain the feeling of burning, lancinating, stabbing, cramping and aching sensation 
(Bridges et al., 2001) which could be paroxysmal or continuous (Schaible and Richter, 
2004). Individuals with neuropathic pain often exhibit hyperalgesia, allodynia or 
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hyperpathia (Ossipov et al., 2000, Brannagan III, 2013). Axotomy or nerve or plexus 
damage, metabolic diseases such as DM or herpes zoster are some of the pathological 
processes leading to neuropathic pain (Schaible and Richter, 2004). It is reported that 
neuropathic pain is amongst the most difficult types of chronic pain to be treated 
(Leung and Cahill, 2010) and impairs the quality of life. 
There are several animal models developed to represent various types of 
neuropathic pain. Numerous studies have applied total nerve transaction and ligation 
to induce the clinical condition of amputation (Wall et al., 1979). Furthermore, partial 
nerve ligation (Seltzer et al., 1990) and spared nerve injury (Decosterd and Woolf, 
2000) have been used to simulate the clinical form involving partial peripheral nerve 
injury. Meanwhile, spinal nerve ligation is developed to mimic the spinal root damage 
to a lumbar disc herniation (Kim and Chung, 1992). Immune or toxin-mediated 
demyelination induces demyelinating neuropathy (Wallace et al., 2003). Furthermore, 
polyneuropathy due to tumour chemotherapy is mimicked by applying vincristine, 
paclitaxel and cisplatin to the animal models (Polomano et al., 2001, Peltier and 
Russell, 2002, Quasthoff and Hartung, 2002). Last but not least, diabetic neuropathy 
is mimicked in animal models by damaging the rodent’s pancreatic insulin-producing 
cells using STZ (Courteix et al., 1993, Rondon et al., 2010).  
 
2.2.1 Mechanism of neuropathic pain 
2.2.1(a) Spinal mechanism 
Peripheral sensitization 
In the normal physiological state, pain sensation is usually elicited by C- and 
Aδ-primary afferent neurons. These two fibres are normally silent in the absence of 
pain stimulation. After the occurrence of a peripheral lesion, however, the dramatic 
23 
 
molecular and cellular changes at the level of primary afferent nociceptor results in 
abnormal oversensitivity of these neurons. Thus, these changes lead to the 
development of pathological spontaneous activity (Baron, 2006) and a large increase 
in the level of spontaneous firing in afferent neurons associated with the site of nerve 
injury (Bridges et al., 2001). 
 The nerve lesion also causes changes in voltage-gated sodium channels that are 
selectively expressed in the nociceptive primary afferent. The damaged, degenerated 
axons, as well as the intact axons in the peripheral nerves as a result of the lesion 
triggers the expression of sodium channels on the damaged C-fibres (Figure 2.4) 
(Baron, 2006). The accumulation of sodium channel clusters occurs at the site of nerve 
lesion as well as within the intact dorsal root ganglion. This Na+ accumulation leads 
to the occurrence of ectopic discharge (Matzner and Devor, 1994). This effect leads to 
the lowering of action potential threshold followed by the occurrence of 
hypersensitivity (Lai et al., 2003).  
Apart from the changes in sodium channels, changes of calcium channels after 
peripheral nerve injury has also been demonstrated to affect the development of 
allodynia and hyperalgesia (Bridges et al., 2001). The diminution of high-voltage 
activated N-type calcium ion (Ca2+) channels together with de novo synthesis of 
rapidly repriming III channels and down-regulation of tetradotoxin-resistant sodium 
ion (Na+) channels after peripheral nerve injury amplifies the excitability of the 
neurons. These effects, in turn, may subsequently lead to an increase in firing 
susceptibility and frequency (indicated by the yellow stars in orange-coloured neurons 
in Figure 2.4) that may result in spontaneous pain and central sensitization (Bridges et 
al., 2001). 
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Figure 2.4 Mechanisms of peripheral and central sensitization in neuropathic pain. 
C-fibres (red) terminate at spinothalamic projection neurons in upper 
laminae (orange neuron), while non-nociceptive myelinated A-fibers 
(blue) project to the deeper laminae. The second-order projection 
neuron is of the wide dynamic range (WDR) type that receives direct 
synaptic signals from nociceptive terminals and also multi-sinaptic 
signal from myelinated A-fibers. γ-aminobutyric acid (GABA)-
releasing interneurons (green) usually exert inhibitory synaptic input 
on the WDR neuron. Moreover, descending modulatory systems 
synapse at the WDR neuron. Spinal cord glial cells (pink) also 
communicate with the WDR neuron. Peripheral changes at primary 
afferent neurons after peripheral nerve damage leads to peripheral 
sensitization (A). Some axons are damaged and degenerated while 
others are still intact and connected with the peripheral end organ 
(skin). The lesion triggers the expression of sodium channels on 
damaged C-fibres. The spontaneous activity of C-fibres induce 
secondary changes in central sensory processing, contributing to spinal 
cord hyperexcitability (central sensitization of second-order WDR 
neurons (indicated by yellow stars in orange-coloured neuron). This 
causes signals from mechanoreceptor A fibres to be perceived as pain 
(mechanical allodynia). Inhibitory interneurons and descending 
modulatory control systems (green neuron) are dysfunctional after the 
nerve damage, thus leading to disinhibition or facilitation of spinal cord 
dorsal horn neurons and further central sensitization. The peripheral 
nerve injury also induces spinal cord non-neuronal glial cells (pink) 
which further augment excitability in WDR neurons by releasing 
cytokines and increasing glutamate levels. Adapted from Baron (2006). 
 
